Blog of Signaling Pathways

Discovery of novel targets and mechanisms of MEK inhibitor Selumetinib for LGG treatment based on molecular docking and molecular dynamics simulation

66 views | Jun 22 2022

Dongdong Zhang et al. thought that CDK2 might be a new direction of Selumetinib in the clinical treatment of LGG. [Read the Full Post]

Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium

99 views | Jun 22 2022

Eric S Schafer et al. found that therapy was well tolerated and effective in pediatric patients with R/R myeloid neoplasms, particularly those with epigenetic alterations, t-AML, and refractory disease. [Read the Full Post]

The efficacy and safety of selumetinib as secondary therapy for late-stage and metastatic non-small cell lung cancer: results from a systematic review and meta-analysis

66 views | Jun 21 2022

Wei-Wei Wang et al.showed that the efficacy of selumetinib was not superior compared to combined therapy for treating NSCLC but did have a better safety profile. [Read the Full Post]

An isogenic panel of App knock-in mouse models: Profiling β-secretase inhibition and endosomal abnormalities

35 views | Jun 20 2022

Naoto Watamura et al. found that multiple factors, including elevated C-terminal fragment β (CTF-β) and humanization of Aβ might influence endosomal alterations in vivo. [Read the Full Post]

BAK plays a key role in A-1331852-induced apoptosis in senescent chondrocytes

52 views | Jun 20 2022

Guihao Wu et al. found that A-1331852 selectively promoted apoptosis in senescent chondrocytes by interfering with the interaction between Bcl-xL and BAK. [Read the Full Post]

Tenofovir alafenamide prophylaxis post-liver transplantation: a real-world study in patients with chronic kidney disease

103 views | Jun 19 2022

E Sinakos et al. found that conversion to TAF in post-LT patients who develop CKD did not lead to improvement of kidney function after a period of one year. [Read the Full Post]

Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer

68 views | Jun 19 2022

Leonie Ratz et al. identified a synthetic lethal interaction between EZH2 and ATM and proposed this synergistic interaction as a novel molecular combination for the treatment of BRCA1-mutant breast cancer. [Read the Full Post]

Construction and evaluation of detachable bone-targeting MOF carriers for the delivery of proteasome inhibitors

163 views | Jun 17 2022

Hongbing Yang et al. provided a potential cascade targeting strategy for improving the delivery effects of bone targeted nanoparticles for the delivery of proteasome inhibitors. [Read the Full Post]

Effect of Lactate Export Inhibition on Anaplastic Thyroid Cancer Growth and Metabolism

43 views | Jun 17 2022

Bixiao Zhao et al. thought that targeting suppression of glycolytic and lactate processing pathways might represent an effective treatment strategy for ATC. [Read the Full Post]

BRAF V600E Mutation-Responsive miRNA-222-3p Promotes Metastasis of Papillary Thyroid Cancer Cells via Snail-Induced EMT

68 views | Jun 16 2022

Yuan Gao et al. found miR-222-3p conduced more aggressive clinical manifestation of PTC by promoting Snail-induced EMT. [Read the Full Post]

Reduction of Metastasis via Epigenetic Modulation in a Murine Model of Metastatic Triple Negative Breast Cancer (TNBC)

100 views | Jun 16 2022

Jessica L S Zylla et al. found that 4SC-202 treatment of tumors from a highly metastatic murine model of TNBC reduced metastasis and warrants further preclinical studies. [Read the Full Post]

Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth

105 views | Jun 15 2022

Yuebo Zhang et al. provided the molecular basis for a novel chemotherapy strategy for PDAC patients. [Read the Full Post]

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

143 views | Jun 15 2022

Soei Gen et al. thought that osimertinib provided better clinical benefits than 1st- and 2nd-generation EGFR-TKIs for patients with EGFR-mutant NSCLC, particularly those with brain or bone metastases and exon 19 deletion. [Read the Full Post]

Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor

96 views | Jun 14 2022

Santhosh A Upadhyaya et al. discovered that single agent alisertib was well tolerated by children with recurrent AT/RT, and SD or PR was observed in approximately a third of the patients. [Read the Full Post]

Combination mTOR and SHP2 inhibitor treatment of lymphatic malformation endothelial cells

48 views | Jun 13 2022

Jennifer K Wolter et al. suggested that combination treatment targeting the PI3K and RAS signaling pathways might result in effective treatment of LMs of the head and neck. [Read the Full Post]

Discovery of precision targeting EZH2 degraders for triple-negative breast cancer

81 views | Jun 13 2022

Cheng Wang et al. found that U3i could degrade PRC2 complex in TNBC cells, induce apoptosis, and cause little damage to normal cells. [Read the Full Post]

Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells

96 views | Jun 12 2022

Zhongbo Du et al. thought that the Notch1 and Notch4 inhibitors GSI-IX and RO4929097 were promising therapeutic agents for the treatment of CRPC. [Read the Full Post]

Synthesis, structural characterization, DFT calculations, molecular docking, and molecular dynamics simulations of a novel ferrocene derivative to unravel its potential antitumor activity

158 views | Jun 12 2022

Mohamed M Hammoud et al. revealed the antitumor potential of ferrocene derivative (10) through targeting and inhibiting mitogen-activated protein (MAP) kinases interacting kinase (Mnk) 1.Communicated by Ramaswamy H. Sarma. [Read the Full Post]

Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes

132 views | Jun 11 2022

Clara Bonanad et al. it is imperative to deepen our knowledge regarding the management of these challenging patients through real-world data and specifically designed geriatric studies to help resolve the questions remaining in their disease management. [Read the Full Post]

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines

70 views | Jun 10 2022

André Fedier et al. found that olaparib exposure was unlikely to produce an acquired resistance phenotype and that PARPi‑sensitive ovarian cancer cells were also cross‑sensitive to non‑platinum and even to compounds not directly interacting with the DNA. [Read the Full Post]